<DOC>
	<DOCNO>NCT01717313</DOCNO>
	<brief_summary>The purpose study assess safety efficacy omarigliptin ( MK-3102 ) , dose once-weekly participant T2DM inadequate glycemic control diet exercise . The primary hypothesis 24 week , treatment omarigliptin compare placebo provide great reduction hemoglobin A1c ( A1C ) .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy Omarigliptin ( MK-3102 ) Participants With Type 2 Diabetes Mellitus ( T2DM ) Inadequate Glycemic Control ( MK-3102-011 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Has type 2 diabetes mellitus Participants India must ≤65 year age Meets one follow criterion : currently antihyperglycemic agent ( AHA ) &gt; = 12 week A1C &gt; =7 % &lt; =10 % stable AHA monotherapy lowdose combination therapy &gt; 12 week A1C &gt; =6.5 % &lt; =9 % Participant one following : male , female reproductive potential , female reproductive potential agrees remain abstinent heterosexual activity use ( partner use ) acceptable contraception prevent pregnancy study 21 day last dose study drug History type 1 diabetes mellitus history ketoacidosis Has treat : thiazolidinedione ( TZD ) within 4 month study participation , glucagonlike peptide1 ( GLP1 ) receptor mimetic agonist dipeptidyl peptidase IV ( DPP4 ) inhibitor within 6 month study participation , insulin sodiumglucose cotransporter inhibitor within 12 week study participation , omarigliptin time prior study participation History hypersensitivity DPP4 inhibitor History intolerance , hypersensitivity contraindication metformin and/or glimepiride sulfonylurea Is weight loss program maintenance phase start weight loss medication past 6 month undergone bariatric surgery within 12 month prior study participation Has undergone surgical procedure within 4 week study participation plan major surgery study Is likely require treatment ≥14 consecutive day repeat course corticosteroid ( inhale , nasal topical corticosteroid permit ) Is currently treat hyperthyroidism thyroid hormone therapy stable dose least 6 week Is expect undergo hormonal therapy preparation donate egg study , include 21 day follow last dose study drug History active liver disease ( nonalcoholic steatosis ) include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease Human immunodeficiency virus ( HIV ) Has new worsen coronary heart disease congestive heart failure within past 3 month , follow disorder within past 3 month : acute coronary syndrome , coronary artery intervention , stroke transient ischemic neurological disorder Has poorly control hypertension History malignancy &lt; =5 year prior study participation , except basal cell squamous cell skin cancer situ cervical cancer Hematological disorder ( aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) Pregnant breastfeeding , expect conceive study , include 21 day follow last dose study drug User recreational illicit drug recent history drug abuse Routinely consume &gt; 2 alcoholic drink per day &gt; 14 alcoholic drink per week , engage binge drinking Has donate blood product phlebotomy within 8 week study participation , intend donate blood product study receive , anticipated receive , blood product within 12 week study participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>